Quintrio
Home

LABORATORY ANALYTICAL INSTRUMENTS

Precipio, Inc. Common Stock

PRPO

Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $18.53 – $20.94
Volume 44,484
Market cap $36M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$35.79M
Price / earnings
—
Price / book
2.41×
Price / sales
1.27×
EV / sales
1.18×
EV / EBITDA
-114.23×

Profitability

Earnings per share
-$0.64
Return on assets
-5.27%
Return on equity
-7.7%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.08×
Current ratio
1.77×
Quick ratio
1.54×
Cash ratio
0.9×

Cash flow

Price / cash flow
21.05×
Price / free cash flow
25.8×
Free cash flow
$1.39M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PRPO, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$7.39M$7.02M$6.96M$6.82M$6.89M$5.63M$4.91M$5.31M
Cost of revenue$4.01M$3.89M$4.24M$3.69M$3.88M$3.2M$2.77M$2.67M
Gross profit$3.38M$3.14M$2.73M$3.13M$3.01M$2.43M$2.14M$2.65M
Selling, general and administrative$0$0$0$0$0$0$0$0
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$3.38M$3.74M$4.15M$2.59M$3.07M$3.25M$3M$2.98M
Operating income$2K-$599K-$1.43M$542K-$61K-$824K-$859K-$336K
Interest expense-$10K$0$0$0-$9K$0$0$0
Income before taxes-$8K-$219K-$1.44M$526K-$79K$74K-$884K-$365K
Income taxes$0$0$0$0$0$0$0$0
Net income-$8K-$219K-$1.44M$526K-$79K$74K-$884K-$365K
Net income attributable to common shareholders-$8K-$219K-$1.44M$526K-$79K$74K-$884K-$365K
EBITDA$314K-$308K-$1.15M$849K$246K-$517K-$535K-$37K
Basic earnings per share$0.00-$0.12-$0.81$0.30-$0.05$0.05-$0.59-$0.24
Diluted earnings per share$0.00-$0.12-$0.81$0.31-$0.05$0.05-$0.59-$0.24

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

PRPO Stock Slips Post Q3 Earnings Despite Revenue and Product Growth

Precipio (PRPO) reported Q3 2026 revenues of $7.3 million, up 8.3% YoY, with near break-even results. The company is transitioning toward growth acceleration, targeting over $40 million in combined annualized revenue run rate by end of 2027. Despite improved liquidity and gross margins, management expressed substantial doubt about going concern status. PRPO plans to double its sales force and leverage distribution partnerships with major healthcare companies.

GlobeNewswire Inc.

Precipio Announces Q3-2026 Shareholder Update Call

Precipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, announced it will host its Q3-2026 shareholder update call on November 10th, 2026. CEO Ilan Danieli highlighted continued revenue growth with the Products Division reaching an important milestone. The call will include company remarks and a moderated live Q&A session, with management providing insights into performance, strategy, and 2027 outlook.

Zacks Investment Research

PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?

Both Precipio and Fulgent Genetics operate in specialty diagnostics with exposure to oncology, but Fulgent Genetics is recommended as the better investment choice. FLGT offers a more diversified growth platform through recent acquisitions (Bako Diagnostics, StrataDx), AI/digital pathology investments, and a therapeutic pipeline, while trading below its historical valuation median. PRPO shows improving fundamentals and cash generation but trades above its five-year median, suggesting its progress is already priced in.

GlobeNewswire Inc.

Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting

Precipio Inc. (NASDAQ: PRPO) is urging shareholders to vote immediately to reach the 50% quorum requirement for its Annual Shareholders Meeting scheduled for June 15, 2026. As of the press release date, only 42% of shares had been voted. The company is seeking to avoid costly adjournment and rescheduling expenses if sufficient votes are not received by the June 14 deadline.

GlobeNewswire Inc.

Precipio to Present at the Planet MicroCap Las Vegas

Precipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, announced it will present at the Planet MicroCap Las Vegas 2026 conference on June 17, 2026. CEO Ilan Danieli and COO Zaki Sabet will host the presentation. The company emphasized it is profitable and focused on raising awareness and building its shareholder base rather than raising capital.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Sep 22, 20231-for-20reverse split
Apr 29, 20191-for-15reverse split